Gilead Reports Strong Q1 and Raised Revenue Guidance, But Cuts Full-Year EPS Outlook by $9.50 Due to Acquisition Costs

summarizeSummary

Gilead reported strong Q1 2026 results with 4% revenue growth and raised its full-year revenue guidance, but drastically cut its full-year EPS guidance by $9.50 per share due to significant acquisition-related IPR&D charges and financing costs.

check_boxKey Events

• Strong First Quarter Financial Results

  Total revenues increased 4% year-over-year to $7.0 billion, driven by higher sales of HIV products, Trodelvy, and Livdelzi. Diluted GAAP EPS was $1.61, up from $1.04 in Q1 2025, and non-GAAP diluted EPS was $2.03, up from $1.81.

• Full-Year Revenue Guidance Raised

  Gilead raised its full-year 2026 product sales guidance to $30.0 billion - $30.4 billion, up from the previous range of $29.6 billion - $30.0 billion, reflecting strong performance and outlook.

• Full-Year EPS Guidance Significantly Reduced

  The company drastically cut its full-year 2026 GAAP diluted EPS guidance to $(3.25) - $(2.85) from $6.75 - $7.15, and non-GAAP diluted EPS to $(1.05) - $(0.65) from $8.45 - $8.85. This reduction of approximately $9.50 per share is primarily due to $11.5 billion in anticipated acquired IPR&D charges and financing costs from recent acquisitions.

• Strategic Acquisitions Detailed

  The filing details the completed acquisition of Arcellx for an implied equity value of $7.8 billion, and new definitive agreements to acquire Tubulis (next-generation ADCs) and Ouro Medicines (T cell engager therapies for autoimmune diseases).

auto_awesomeAnalysis

Gilead Sciences delivered a strong first quarter, surpassing revenue expectations and raising its full-year revenue guidance. This positive performance was driven by robust HIV product sales, particularly Biktarvy and Descovy, and strong growth in Trodelvy. However, the company significantly reduced its full-year GAAP and non-GAAP diluted EPS guidance by approximately $9.50 per share, shifting from positive to negative earnings projections. This substantial reduction is attributed to anticipated acquired in-process research and development (IPR&D) charges of $11.5 billion and financing costs related to recent strategic acquisitions, including Arcellx, Ouro Medicines, and Tubulis. While these acquisitions are intended to strengthen Gilead's oncology and inflammation pipelines, the immediate and material impact on profitability will likely be a primary focus for investors, creating a mixed but highly impactful signal.